Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| VIKING GLOBAL INVESTORS LP | 29.99M | $643.0M | 18.86% | -- | 2026-06-30 |
| BlackRock, Inc. | 15.14M | $324.0M | 9.52% | +1.84M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.40M | $137.0M | 4.03% | +309.4K | 2026-06-30 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.91M | $126.0M | 3.72% | +2.05M | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.48M | $117.0M | 3.44% | +984.8K | 2026-06-30 |
| D. E. Shaw & Co., Inc. | 4.63M | $99.0M | 2.91% | +2.66M | 2026-06-30 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 4.27M | $91.0M | 2.68% | -1.17M | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 3.64M | $78.0M | 2.29% | +5.8K | 2026-06-30 |
| STATE STREET CORP | 3.46M | $74.0M | 2.17% | +231.1K | 2026-06-30 |
| UBS Group AG | 3.13M | $67.0M | 1.97% | +2.90M | 2026-06-30 |
